BioCryst Pharmaceuticals (BCRX) has risen sharply, recording gains of 40.58% in the past 4 weeks. However, the stock has corrected -14.09% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 40.05% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week.
BioCryst Pharmaceuticals, Inc. is up 30.42% in the last 3-month period. Year-to-Date the stock performance stands at -58.04%. The stock has recorded a 20-day Moving Average of 6.62% and the 50-Day Moving Average is 27.82%.
BioCryst Pharmaceuticals (NASDAQ:BCRX): The stock opened at $4.36 on Friday but the bulls could not build on the opening and the stock topped out at $4.47 for the day. The stock traded down to $4.28 during the day, due to lack of any buying support eventually closed down at $4.33 with a loss of -0.69% for the day. The stock had closed at $4.36 on the previous day. The total traded volume was 584,379 shares.
Also, Major Brokerage house, PiperJaffray upgrades its ratings on BioCryst Pharmaceuticals (NASDAQ:BCRX). According to the latest information available, the shares are now rated Overweight by the analysts at the agency. Previously, the analysts had a Neutral rating on the shares. The rating by the firm was issued on August 12, 2016.
BioCryst Pharmaceuticals, Inc. (BioCryst) is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment rare diseases. The Company uses X-ray crystallography, computer modeling of molecular structures and advanced chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology. Its products include RAPIVAB, BCX4161, BCX7353 and other second generation HAE compounds, BCX4430 and Forodesine. Peramivir is an intravenous neuraminidase inhibitor approved in multiple countries for the treatment of patients with influenza, in the United States as RAPIVAB, in Japan as RAPIACTA and in Korea as PERAMIFLU. BCX4161 is the Companys Hereditary Angioedema (HAE) product candidate. BCX7353 is a plasma kallikrein inhibitor. Forodesine is a Purine Nucleoside Phosphorylase (PNP) inhibitor.